Details of the Drug Reposition

General Information of This Drug (ID: DM3PJSE)

Drug Name
TP-271   DM3PJSE
Synonyms
UNII-Y6IUM7395Q; Y6IUM7395Q; 1207284-17-0; (S)-N-((5aR,6aS,7S,10aS)-9-carbamoyl-7-(dimethylamino)-4-fluoro-1,8,10a,11-tetrahydroxy-10,12-dioxo-5,5a,6,6a,7,10,10a,12-octahydrotetracen-2-yl)-1-methylpyrrolidine-2-carboxamide; (2S)-N-((5aR,6aS,7S,10aR)-9-carbamoyl-7-(dimethylamino)-4-fluoro-1,10,10a,12-tetrahydroxy-8,11-dioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl)-1-methylpyrrolidine-2-carboxamide; (2S)-N-[(5aR,6aS,7S,10aR)-9-carbamoyl-7-(dimethylamino)-4-fluoro-1,10,10a,12-tetrahydroxy-8,11-dioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-1-methylpyrrolidine-2-carboxamide; CHEMBL2057236; SCHEMBL13397803; GTPL11013; TP271; DB15040
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Respiratory tract infection DIS7OJYM CA45 Phase 1 [1]
Pneumonia DIS8EF3M CA40 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03234738) A Phase 1 Safety and PK Study of IV TP-271. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02724085) A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271. U.S. National Institutes of Health.